GNRHR rs2292075: What Your Genotype Means
The genetic variant rs2292075 is a common single-nucleotide polymorphism located in the gonadotropin-releasing hormone receptor (GNRHR) gene on chromosome 4. As an exonic synonymous variant, it does not alter the underlying amino acid sequence of the receptor protein. Scientific investigations have primarily focused on whether this variant correlates with subtle differences in reproductive hormone signaling, pubertal timing, or ovarian stimulation response during assisted reproductive technologies.
What each genotype means
Typical GnRH receptor profile
You carry two copies of the common A allele for this synonymous variant in the GNRHR gene. In reproductive genetics studies, this genotype reflects typical receptor sequence background and baseline ovarian stimulation responses. The overall clinical impact of this variant remains limited and variable across different populations.
Carried by approximately 55% to 65% of individuals of European ancestry and roughly 40% to 50% in East Asian populations.
Intermediate receptor response marker
You carry one copy of the G allele alongside the reference A allele. Research evaluating ovarian stimulation in assisted reproductive technology has investigated this genotype for subtle differences in gonadotropin requirements, though published evidence is modest and inconsistent. Any fertility or hormonal medication dosing decisions should always be reviewed directly with your treating clinician or reproductive endocrinologist.
Found in approximately 30% to 35% of people of European descent and up to 45% in certain East Asian groups.
Homozygous variant receptor profile
You carry two copies of the G allele for this synonymous coding variant. Small exploratory studies have evaluated whether homozygous carriers display altered sensitivity during controlled ovarian stimulation protocols, but findings are preliminary and have not established clinical significance. If you undergo treatment involving GnRH analogs, discuss your individual protocol and medication responses directly with your specialist.
Observed in roughly 4% to 6% of European individuals and approximately 10% to 15% of East Asian populations.
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs2292075 resides within the coding region of the GNRHR gene on chromosome 4q13.2. Identified molecularly as c.780A>G, this change represents a transition between adenine and guanine. At the translational level, the variation is annotated as p.Leu260=, denoting a synonymous change: both the reference and alternate codons specify the amino acid leucine at position 260. Because synonymous changes do not alter primary polypeptide structure, they generally do not cause overt protein misfolding or disruption of ligand binding. Instead, researchers hypothesize that such silent substitutions might occasionally modulate gene expression through subtle mechanisms such as mRNA transcript stability, secondary RNA folding structures, or localized ribosome translation kinetics. In public variant catalogs like dbSNP and ClinVar, rs2292075 is tracked as a common human sequence variation rather than an overt, high-penetrance disease-causing mutation.
Biological Function of the GNRHR Gene
The GNRHR gene encodes the gonadotropin-releasing hormone receptor, a critical seven-transmembrane G-protein coupled receptor embedded within the plasma membrane of anterior pituitary gonadotroph cells. When endogenous gonadotropin-releasing hormone (GnRH) is released in pulsatile bursts from the hypothalamus, it binds to GNRHR, triggering downstream intracellular signaling cascades such as inositol phosphate production and calcium mobilization. This signaling directly stimulates the synthesis and pulsatile secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In turn, LH and FSH govern gametogenesis, gonadal steroid synthesis, follicular development, and overall reproductive maturation. Disruption of this physiological axis—typically through severe biallelic loss-of-function mutations—can result in congenital conditions such as idiopathic hypogonadotropic hypogonadism (IHH). Common variations within the pathway, however, tend to exert far smaller physiological ripples.
Current Scientific Evidence and Clinical Strength
Evidence evaluating the phenotypic impact of rs2292075 remains strictly limited and observational. Several candidate-gene association studies have evaluated whether carrying the G allele correlates with altered sensitivity to GnRH agonists or antagonists during in vitro fertilization (IVF) ovarian stimulation protocols, as well as broader reproductive traits like age at menarche. Across published literature, reported associations have shown small effect sizes, modest statistical significance, and frequent failures of replication across independent cohorts. Broad-scale genome-wide association studies (GWAS) and systematic reviews have not confirmed rs2292075 as an independent, clinically actionable driver of reproductive disorders or pubertal delay. Therefore, current consensus views this variant as a benign background polymorphism or, at most, a low-impact trait marker whose theoretical contributions to reproductive variation are dwarfed by complex polygenic and environmental influences.
Distribution Across Global Populations
The rs2292075 variant is widely distributed across global human populations with notable differences in allele frequencies. According to reference resources including the 1000 Genomes Project and gnomAD, the minor G allele occurs at an estimated frequency of approximately 0.22 (22%) among populations of European ancestry. In contrast, higher frequencies have been observed in certain East Asian populations, where the G allele frequency reaches approximately 0.35 (35%) or higher. Consequently, homozygous reference individuals (AA) represent the majority in European cohorts, whereas heterozygous (AG) and homozygous variant (GG) genotypes are relatively frequent across diverse global backgrounds. These population-specific frequency differences highlight why genetic findings from single-ancestry candidate studies cannot be universally applied without careful multi-ancestry validation.
Interpreting Your Genetic Results
Finding rs2292075 in personal genomic data should be viewed through an educational rather than a diagnostic lens. The presence of one or two copies of the G allele does not signify reproductive dysfunction, infertility, or an inherited endocrine disorder. Routine medical decisions, including family planning, fertility workups, and ovarian stimulation protocols, are guided by standardized clinical diagnostics—such as serum hormone panels, pelvic imaging, and clinical history—rather than common synonymous polymorphisms. Individuals undergoing assisted reproductive technologies or hormonal therapies should never adjust medications based on direct-to-consumer genetic findings. Any questions regarding reproductive health, hormonal balances, or medication choices should always be evaluated in partnership with a qualified reproductive endocrinologist, physician, or certified genetic counselor.
How common is this variant?
The minor G allele has an estimated frequency of approximately 0.22 in European populations, while reaching up to 0.35 or higher in certain East Asian groups.
Frequently asked questions
Does having the G allele of rs2292075 mean I will struggle with fertility?
No. The G allele is a common, synonymous variant that does not alter the structure of the GNRHR protein. It is not considered a causative factor or diagnostic marker for infertility.
What is the difference between an exonic synonymous variant and a pathogenic mutation?
An exonic synonymous variant alters the DNA sequence in a gene's coding region without changing the resulting amino acid, meaning the finished protein is identical. Pathogenic mutations typically alter amino acids, introduce premature stop signals, or disrupt splicing, directly damaging protein function.
Can this genetic variant influence how I respond to IVF medications?
Some small candidate studies explored whether rs2292075 correlates with gonadotropin dosage or egg yield during ovarian stimulation, but findings are inconsistent. Current professional fertility guidelines do not recommend altering medication protocols based on this SNP.
Should I speak with a doctor if my raw genetic data shows rs2292075?
There is no clinical necessity to seek medical attention solely because of this variant, as it is classified as benign. However, if you have broader questions about your reproductive health or hormone levels, consulting a physician or genetic counselor is always recommended.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2292075?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GNRHR
Pathogenic missense substitution (p.Arg262Gln) in GNRHR linked to autosomal recessive normosmic congenital hypogonadotropic hypogonadism.
Gonadotropin-releasing hormone receptor variant associated with altered gonadotropin pulsatility and susceptibility to delayed puberty.
Recessive pathogenic missense variant in gonadotropin-releasing hormone receptor causing normosmic idiopathic hypogonadotropic hypogonadism and delayed puberty.
A missense variant (p.Gln106Arg) in the gonadotropin-releasing hormone receptor associated with normosmic congenital hypogonadotropic hypogonadism.
Common missense variant (p.Gln106Arg) in the gonadotropin-releasing hormone receptor associated with hypogonadotropic hypogonadism and delayed puberty when compound heterozygous.
Pathogenic missense variant disrupting GnRH binding in the pituitary gonadotropes, causing severe hypogonadotropic hypogonadism.